Literature DB >> 3057899

Sleep apnea and hypothyroidism: mechanisms and management.

R R Grunstein1, C E Sullivan.   

Abstract

PURPOSE: There is a high incidence of sleep apnea in patients with untreated hypothyroidism. Thyroxine treatment is said to significantly reduce the apnea index and length and sleep apnea symptoms. We undertook a review of 10 consecutive hypothyroid patients with sleep apnea to investigate mechanisms and management of these two disorders. PATIENTS AND METHODS: Polysomnograms were obtained in 10 consecutive hypothyroid patients referred to our sleep disorders unit. All patients were studied while hypothyroid. Eight patients were restudied later when euthyroid. Lung function, blood gas values, and awake supraglottic resistance were also assessed in each patient.
RESULTS: All 10 patients had sleep apnea and were treated with thyroxine. In one patient, hypothyroid myopathy involving the upper airway was demonstrated to be a potential mechanism of sleep apnea in hypothyroidism. Nocturnal angina and ventricular arrhythmias developed in two patients, despite the use of low thyroxine doses. Nasal continuous positive airways pressure (CPAP) was begun in eight patients. Initiation of CPAP prevented further angina or arrythmia in the patients with these cardiac complications. Six of the eight patients who were available for follow-up studies had persistent sleep apnea despite an euthyroid status (apnea index before thyroxine, 51 +/- 6; apnea index after thyroxine, 45 +/- 8), and CPAP therapy was continued in these patients.
CONCLUSION: Our experience suggests that the apnea index does not decrease significantly in all patients with hypothyroidism and sleep apnea when euthyroidism is achieved. Treatment of hypothyroidism in the presence of sleep apnea is potentially hazardous and may lead to cardiovascular complications. Management by a combination of CPAP and low-dose thyroxine is helpful in this situation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3057899     DOI: 10.1016/s0002-9343(88)80020-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  17 in total

Review 1.  Treatment options for sleep apnoea.

Authors:  R R Grunstein; J Hedner; L Grote
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Sleep apnea syndrome and hypothyroidism.

Authors:  Fabio Lanfranco
Journal:  Endocrine       Date:  2013-10-12       Impact factor: 3.633

3.  Influence of subclinical hypothyroidism and T4 treatment on the prevalence and severity of obstructive sleep apnoea syndrome (OSAS).

Authors:  O Resta; P Carratù; G E Carpagnano; M Maniscalco; G Di Gioia; D Lacedonia; R Giorgino; G De Pergola
Journal:  J Endocrinol Invest       Date:  2005-11       Impact factor: 4.256

4.  SLEEP DISORDERED BREATHING AND METABOLIC EFFECTS: EVIDENCE FROM ANIMAL MODELS.

Authors:  Jonathan Jun; Vsevolod Y Polotsky
Journal:  Sleep Med Clin       Date:  2007-06

5.  Neuroendocrine alterations in obese patients with sleep apnea syndrome.

Authors:  Fabio Lanfranco; Giovanna Motta; Marco Alessandro Minetto; Matteo Baldi; Marcella Balbo; Ezio Ghigo; Emanuela Arvat; Mauro Maccario
Journal:  Int J Endocrinol       Date:  2010-02-23       Impact factor: 3.257

Review 6.  Impact of concomitant medications on obstructive sleep apnoea.

Authors:  Ingrid Jullian-Desayes; Bruno Revol; Elisa Chareyre; Philippe Camus; Céline Villier; Jean-Christian Borel; Jean-Louis Pepin; Marie Joyeux-Faure
Journal:  Br J Clin Pharmacol       Date:  2016-11-24       Impact factor: 4.335

Review 7.  Anaesthetic management of patients with sleep apnoea syndrome.

Authors:  N N Boushra
Journal:  Can J Anaesth       Date:  1996-06       Impact factor: 5.063

Review 8.  Obstructive sleep apnoea.

Authors:  S G McNamara; R R Grunstein; C E Sullivan
Journal:  Thorax       Date:  1993-07       Impact factor: 9.139

Review 9.  Diagnosis of obstructive sleep apnea.

Authors:  H W Bonekat; P E Krumpe
Journal:  Clin Rev Allergy       Date:  1990 Summer-Fall

Review 10.  Central sleep apnea in patients with congestive heart failure.

Authors:  Safwan Badr
Journal:  Heart Fail Rev       Date:  2008-08-29       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.